This work uncovers a link between NECTIN4 expression with BRAFV600E mutation and with BRAFi resistance in melanoma, and provides a rationale for using NECTIN4-targeted drugs to treat melanoma with high NECTIN4. The gene discussed is NECTIN4; the disease is melanoma.